Who are P-Gemox's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Cisplatin / Carboplatin，Gemcitabine，Cindilimab, PTH followed by dose dense AC of FEC, Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone, SOX Chemotherapy, chemotherapy of mFOLFOX6 or FOLFIRI, CEV chemotherapy.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/p-gemox.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

P-Gemox — Competitive Intelligence Brief

P-Gemox (P-Gemox) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination chemotherapy. Area: Oncology.

phase 3 Combination chemotherapy Oncology Small molecule Live · refreshed every 30 min

Target snapshot

P-Gemox (P-Gemox) — The First Affiliated Hospital with Nanjing Medical University. P-Gemox is a combination chemotherapy regimen that combines gemcitabine and oxaliplatin to inhibit DNA synthesis and induce apoptosis in cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
P-Gemox TARGET	P-Gemox	The First Affiliated Hospital with Nanjing Medical University	phase 3	Combination chemotherapy
Cisplatin / Carboplatin，Gemcitabine，Cindilimab	Cisplatin / Carboplatin，Gemcitabine，Cindilimab	People's Hospital of Quzhou	marketed	Combination chemotherapy with immune checkpoint inhibitor	DNA (platinum agents, gemcitabine); PD-L1 (cindilimab)
PTH followed by dose dense AC of FEC	PTH followed by dose dense AC of FEC	Agendia	marketed	Combination chemotherapy regimen with monoclonal antibody	HER2 receptor; microtubule; DNA (topoisomerase II)
Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone	Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone	Technische Universität Dresden	marketed	Combination chemotherapy (nucleoside analog + topoisomerase II inhibitors)	DNA polymerase (cytarabine); Topoisomerase II (amsacrine, mitoxantrone)
SOX Chemotherapy	SOX Chemotherapy	The First Affiliated Hospital with Nanjing Medical University	marketed	Combination chemotherapy regimen
chemotherapy of mFOLFOX6 or FOLFIRI	chemotherapy of mFOLFOX6 or FOLFIRI	Xu jianmin	marketed	Combination chemotherapy regimen	Thymidylate synthase (5-FU), DNA topoisomerase I (irinotecan), DNA (oxaliplatin)
CEV chemotherapy	CEV chemotherapy	Sun Yat-sen University	marketed	Combination chemotherapy regimen

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination chemotherapy class)

Children's Cancer Group, China · 1 drug in this class
EpicentRx, Inc. · 1 drug in this class
Sumitomo Pharma (Suzhou) Co., Ltd. · 1 drug in this class
Taiho Pharmaceutical Co., Ltd. · 1 drug in this class
The First Affiliated Hospital with Nanjing Medical University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). P-Gemox — Competitive Intelligence Brief. https://druglandscape.com/ci/p-gemox. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab